|
Spinal Cord Tumors and Tumors of the Bone of the Spinal Column are
an area of specific interest for Dr. Martin L. Lazar and the staff of
Neurosurgical Consultants. Their successful treatment in most cases of
Intraspinal Tumors involves the use of highly advanced Minimally
Invasive Microsurgical Techniques. The majority of these patients
undergo a UNILATERAL (one-sided) APPROACH. This revolutionary
concept in Neurosurgery greatly limits the amount of surgical exposure
required and therefore limits the amount of tissue (including the
muscles of the spine) that are touched and retracted during the
operation. This results in less post-operative pain, earlier
mobilization, diminished hospital stay, less risk for complications,
an earlier return to activities as well as lower overall costs.
The following information is provided as part of Neurosurgical
Consultants' Patient Information Program.
Spinal tumors are usually classified by their relationship to the
spinal cord and its coverings. The spine is composed of individual
bones (Vertebrae) stacked one on top of the other in a column.
Each vertebra consists of an oval shaped vertebral body, which lies
in the front (anterior) part of the vertebra. The vertebral body is
the major weight bearing portion of the vertebra. The back (posterior)
portion to the vertebra consists of an arch of bone (Lamina and
Spinous process), which protect the spinal cord and its
coverings. The bony arch of each vertebra is connected to the body
by two small columns of bone (Pedicles). The Spinal Canal
(the circular center portion of the vertebra) is formed by the two
(2) Lamina on either side in the back, the pedicles on both sides
and the vertebral body in the front. The spinal cord and its nerve
roots are contained within the spinal canal and are covered by a
fibrous tubular membrane called "Dura Mater".
One convenient way to understand this anatomy is to consider that
the Spinal Cord and Spinal Nerves live within a "house made of bone"
(the Spinal Canal). The "roof" of the house is formed by the Lamina.
The "walls" are formed by the Pedicles and the "basement" by the
Vertebral Body. A pair of Spinal Nerves will exit the Spinal Canal
at every vertebral level through "windows" in the "walls" which are
formed by the pedicles of adjacent vertebrae.
Tumors that are located within the Spinal Canal and outside the
Dura Mater are called Intraspinal Extradural Tumors.
Most of these are metastatic tumors (cancerous tumors which have spread from
another organ), which arise within the vertebrae themselves.
Tumors arising inside the dura mater, but outside the actual
substance of the spinal cord are termed Intradural-Extramedullary
Tumors. The majority of these tumors are Neurofibromas (nerve
sheath tumors) or Meningiomas. Tumors arising within the substance
of the spinal cord itself are called Intramedullary Tumors.
These are usually Astrocytomas or Ependymomas.
It is important to understand that different types of tumors often
behave differently and may require treatments that are specific to
the characteristics of that tumor. Details of these various types
of tumors are explained in more detail in the following material.
- Spinal cord tumors are less common than brain tumors. About
10,000 Americans develop primary spinal cord or metastatic spine
tumors each year.
- Although spinal cord tumors affect people of all ages, they
are most common in young and middle-aged adults. (National Institute
of Neurological Disorders and Stroke)
- Spinal cord tumors, while rare, can leave patients severely
impaired neurologically. Modern neuroimaging capabilities (such as
MRI and CT Scanning) have allowed these lesions to be diagnosed
earlier thus permitting more timely intervention.
- Advanced Minimally Invasive Microsurgical Techniques
and other specialized treatments can help to minimize the effects
of these potentially devastating types of tumors.
- These are tumors that derive from cells within the spine/spinal cord
- 90 percent of primary spinal cord tumors are BENIGN.
- The most common primary spinal cord tumors are Intradural
Extra-medullary (located within the covering of the spinal cord,
the Dura Mater, but outside the substance of the spinal cord itself.)
The most common of these are Meningiomas, Neurofibromas
and Schwannomas.
- The majority of these tumors are slow growing, although some
spinal cord tumors can grow rapidly.
- Malignant primary central nervous system (Brain & Spinal
Cord) tumors rarely spread out to other body parts although
some can "seed" themselves within the Cerebrospinal Fluid pathway
that surrounds the brain and spinal cord. (National Institute of
Neurological Disorders and Stroke)
- Men & women are affected equally by benign spinal cord tumors
except for Meningiomas which disproportionately affect more
women.
- The THORACIC region of the spine is involved more frequently
than the CERVICAL region by these tumors. The LUMBO-SACRAL region
is the least affected.
Astrocytoma |
Cells of the tissue that supports nerve cells |
Cancerous or noncancerous |
Children and adults |
Ependymoma |
Cells lining the canal in the center of the spinal cord |
Noncancerous |
Children and adults |
Hemangioblastoma |
Blood vessel cells |
Noncancerous |
Children and adults |
Meningioma |
Cells of the layers of tissue covering the spinal cord (meninges) |
Noncancerous but may recur |
Children and adults |
Neurofibroma |
Cells that support peripheral nerves |
Usually noncancerous |
Children and adults (occurs in neurofibromatosis) |
Sarcoma |
Cells of connective tissue in the spine |
Cancerous |
Children and adults |
Schwannoma |
Cells that form the myelin sheath around nerve fibers (Schwann cells) |
Usually noncancerous |
Children and adults |
- Malignant tumor cells arising elsewhere in the body can easily spread (metastasize) to within the substance of the brain and the bone of the spinal column; however, they rarely spread to the substance of the spinal cord itself.
- Metastatic Spine tumors occur in 10 percent of cancer patients.
- For every four people who have cancer that has spread somewhere
within the body, one also develops metastasis within the central
nervous system. The two most common metastatic tumors to the Brain
and Spine are from lung and breast cancers. (National Institute of
Neurological Disorders and Stroke)
- Ten (10) percent of cancer patients with metastatic tumors to
the spine have NO PREVIOUS KNOWN CANCER and of these, spinal cord
compression and pain are the first signs & symptoms of the disease.
Spinal bone tumors involve the bony vertebral column and can
be divided into cancerous tumors and benign tumors. Cancerous spinal
bone tumors include metastatic cancers and primary bone cancers.
Although any type of cancer can spread to spinal bones, the most
common ones are cancers of lung, breast, prostate and kidney as well
as lymphomas.
Metastatic cancer is usually impossible to "cure". However,
surgical debulking of the tumor (with or without mechanical spine
stabilization) in order to remove any pressure on the spinal cord,
can improve quality of life. Operative therapy may also consist
of placement of acrylic material or banked bone and metallic
implants to preserve the stability of the spine, following removal
of the portion of the vertebra involved with tumor. For metastatic
tumors which do not compress the spinal cord or destabilize the
spine, radiation therapy often significantly reduces
spinal pain. The technical advances in STEREOTACTIC
RADIOSURGERY have particular relevance for radiation of the spine
by diminishing the risk of damage to the spinal cord
(http://www.cksociety.org/).
Primary cancerous spinal bone tumors are relatively
uncommon and include chordomas, osteogenic sarcomas,
chondrosarcomas, Ewing's sarcomas, multiple myelomas, lymphomas etc.
Treatments for these malignant tumors must involve multimodality
measures which, includes surgery, chemotherapy and radiation.
Benign spinal bone tumors include osteoid osteomas,
osteoblastomas, osteochondromas, giant cell tumors, aneurysmal
bone cysts, plasmacytomas, hemangiomas, etc. Treatments for these
benign tumors must be individualized depending on the type of
pathology and their symptoms. Benign tumors of the spinal column
can often be totally removed.
Meningiomas and nerve sheath tumors (Schwannomas
and Neurofibromas) comprise the overwhelming majority of
this subset of spinal tumors. Meningiomas arise from the arachnoid
(a thin covering layer of the spinal cord which is located
inside the dura) and are most common in middle aged and elderly
women. The Thoracic portion of the vertebral column is the most
commonly affected part of the spine. Schwannomas and Neurofibromas
arise from the nerve roots which come off the spinal cord.
Neurofibromas can occur as a sporadic condition or as a genetic
disorder such as Neurofibromatosis
http://www.nfinc.org/.
Meningiomas, Neurofibromas and Schwannomas are almost always entirely
histologically benign. There are some additional, although exceptionally
rare, tumors that are included in this group of benign tumors such as
Hemangioblastomas, Epidermoids and Dermoids.
All of these tumors are considered to be benign and most can be
successfully removed surgically using advanced Minimally Invasive
Microsurgical Techniques.
The three most common types of intramedullary spinal cord tumors
are low-grade astrocytomas, ependymomas, and high-grade
astrocytomas.
Astrocytomas and Ependymomas account for the majority
and occur with about equal frequency. Hemangioblastomas are
less common and sometimes occur in conjunction with Von Hippel
Lindau disease (a disease in which patients are prone to developing
cysts in the kidney and other organs
http://www.vhl.org).
Intramedullary tumors occur most often in the cervical spinal cord
and are often relatively benign.
These tumors usually arise, within the substance of the spinal cord
itself, from cells known as "GLIAL CELLS". This series of cells
comprises the "glue" or structural "support" cells of the Central
Nervous System (CNS), in contradistinction to the "Neurons", which
are the "action" cells of the brain and spinal cord. Glial cells
are the most common cellular component of the brain. They are five
to ten times more frequent than the trillion brain neurons and
comprise half the central nervous system (CNS) by volume. There
are three (3) different cell types in this cell series. The
"Astrocyte" was so named, because it resembles the shape of a
star, when looked at under a microscope. The next most common
cell in this series is the "Ependymal Cell", which lines the
cavities of the brain (called ventricles). These are normal
chambers within the brain, where cerebrospinal fluid (CSF) is
manufactured. These cells are also found within the central canal
(a small cavity) within the spinal cord. The last cell type is the
"Oligodendrgogliocyte" (Oligo), which is the cell within the
brain and spinal cord responsible for making the insulating material
(called Myelin), that surrounds the fibres (axons) which
transmit electrical impulses within the brain and spinal cord.
Each of these cell types is capable of forming a tumor. The
Neurosurgeons of Neurosurgical Consultants regard ALL OF THESE AS
MALIGNANT TUMORS. The degree of malignancy, and therefore, biological
aggressiveness can vary from quite indolent to extremely
aggressive. These tumors are generally categorized according to
their degree of aggressiveness, as judged by a number of factors.
Neuropathologists (specialists trained to examine these tumors
under powerful microscopes), have tended to "grade" these tumors
from 1 to 4, with "4" being the most aggressive and "1" being the
least malignant. All of these tumors have a tendency to "infiltrate"
within the brain and/or spinal cord by tracking along the fibre
pathways that interconnect every part of the brain to every other
part of the brain. Very rarely do these tumors ever spread beyond
the brain or spinal cord.
Tumor grading is important for prognosis and therapy. Tumors are
graded by microscopic examination of the tumor specimen. The
specimen is evaluated for the most malignant components. Varying
"grades" of tumor cells can be found in any one tumor. The
biological behaviour of the tumor will relate to the highest
grade (worst and most aggressive) component of that tumor, even
though that higher grade component comprises a small portion of
the entire tumor. In other words, if a tumor is 99.5% Grade 1
and only 1/2 percent Grade 3 or 4, the biological behaviour of
that tumor, will be as if the entire tumor is Grade 3 or Grade 4.
These tumors can be difficult to diagnose early in the course of
the disease process, since the clinical features of intramedullary
spinal cord tumors are variable. Early symptoms are usually
nonspecific and may only subtly progress. Symptom duration before
diagnosis is often 2 to 3 years, whereas malignant or metastatic
neoplasms cause problems within a much shorter course, usually in
several weeks to a few months.
Pain is the most common presenting symptom of intramedullary spinal
cord tumors in adults. The pain typically localizes to the level
of the tumor. Sensory or motor (weakness and spasticity) complaints
are the initial symptoms in up to one third of patients. Upper
extremity symptoms predominate in cases of cervical neoplasms.
One sided or asymmetrical involvement is common. Thoracic cord
tumors produce spasticity and sensory changes. Numbness is a
common complaint and usually begins in the more peripheral
locations of the lower extremities. Tumors of the lumbar region
and conus medullaris present with back and leg pain. Bladder and
bowel dysfunction tends to occur early.
A careful history and physical examination is the first step in
diagnosis. MRI scanning without and with contrast agent
(Gadolinium) is the primary method to diagnose these tumors. MRI
generally offers excellent anatomical details regarding the
position of the tumor and its relationship to the spinal cord.
Ependymomas are tumors that arise from Ependymal cells, which make up
the thin layer of epithelium that lines the central canal of the
spinal cord. Ependymal cells are the third type of cell in the
"glial" cell series, the others being Astrocytes and Oligodendrocytes.
In a manner similar to other "Gliomas", Ependymal Cells can form
a tumor called "Ependymoma". These tumors comprise approximately
60% of spinal cord gliomas, 96% occur in adults.
Ependymomas have the potential to spread ("seed") through the CSF
(Cerebrospinal Fluid that surrounds the cord) pathway to other
areas of the nervous system.
Ependymomas can spread (a process called "seeding") to other
regions of the spinal cord through the spinal fluid. There are a
number of varieties of ependymoma recognized by the World Health
Organization.
The papillary ependymoma (the most common) occurs in the
brain and spinal cord, while the myxopapillary ependymoma
occurs only at the bottom of the spine.
The subependymoma is a common finding at autopsy and a rare
cause of surgical intervention. Finally there is the anaplastic
ependymoma, a more aggressive tumor.
These are tumors that arise from ependymal cells within the substance
of the spinal cord and are the most common intramedullary tumor
in adults. These tumors, which affect men and women equally, occur
throughout life, but are more frequently seen in the middle adult
years.
Spinal Cord Ependymoma is more likely to occur in the thoraco-lumbar
junction region and involve the "Cauda Equina". The most common
presenting complaint is that of "PAIN". Weakness and/or tingling
in the lower extremities, bowel and bladder control may also be
noted. MRI scan is the most effective diagnostic screening method
and is often done when the tentative diagnosis is thought to be
a herniated lumbar disc.
Treatment demands surgical excision to the maximum extent possible.
Minimally invasive microendoscopic spinal cord removal techniques
are now available. Nevertheless, not all tumors can be entirely
removed. For those where some residual is known, or believed to be
present, then radiation and chemotherapy should be serious
considerations.
The Neurosurgeons of Neurosurgical Consultants have a particular
interest in and significant experience with Spinal Cord
Ependymomas.
Ependymomas rank second only to Medulloblastomas in sensitivity to
radiation. Radiation Therapy is administered after surgical excision
to the tumor bed and if any metastases ("SEEDING") through the CSF
are found. In 50% of patients survival time was 2 years longer with
radiation therapy than without.
The overall 5-year survival rate is 45%. Tumor recurrence or
progression at the primary site is by far the most common cause of
death in these patients. Spinal seeding is relatively uncommon and
occurs later in the course of the disease for most patients.
These tumors differ from other ependymomas by their location within
the Filum Terminale, a neurologically non-functioning structure at
the lower-most end of the spinal cord.
The role of surgery for Filum Terminale Ependymomas depends
on the size of the tumor and its relationship to the surrounding
roots of the cauda equina. We strongly favor Minimally Invasive
Microsurgical Gross Total Resection when possible. Complete
surgical resection can be accomplished with small and moderate-sized
tumors that remain well circumscribed within the fibrous coverings
of the Filum Terminale and are separable from the cauda
equina nerve roots. Large tumors can present significant problems
for surgical resection. These tumors have been present for many
years and present a risk for spread through the cerebrospinal
fluid. Filum Terminale Ependymomas that are large and
adherent to many nerves can make total removal difficult to
impossible without considerable damage to the nerve roots to which
they are densely adherent. While many can be safely and completely
resected, those that cannot and should not be totally resected,
can be treated with post-operative radiation therapy and
chemotherapy.
Even in cases where the tumor can be removed totally, a recurrence
rate of at least 20% can be anticipated.
Biologically aggressive tumors, which are more common in younger
patients, can recur early after removal. Radiation therapy is an
important adjunct for these patients as well as those in whom a
significant amount of tumor is left behind during the operation.
Neuro-oncologic chemotherapy, an option available in some centers,
is the third arm of a comprehensive effort to prolong and maintain
a high quality of life.
Traditional management has been to use "standard" forms of
chemotherapy. Currently there are some unconventional chemotherapeutic
alternatives that offer considerable hope for improved quality
and length of survival. New therapies such as Temodar
(temozolamide), Avastin (bevacizumab which is an
anti-angiogenesis medication) and CPT-11 are currently
being used by one of our Neuro-oncologists either alone (or more
commonly) in combination or with other drugs, to produce encouraging
results.
These are tumors that arise from cells called Astrocytes,
which are normally found within the substance of the spinal cord.
Approximately 3% of central nervous system astrocytomas arise within
the spinal cord. Spinal Cord Astrocytomas occur at any age, but are
more common during the early years of life. They are by far the most
common intramedullary spinal cord tumor in children. They account
for 90% of all intramedullary tumors in patients younger than 10
years of age and 60% of the intramedullary neoplasms in adolescents.
Almost 60% of these tumors are located in the cervical and
cervicothoracic spinal cord segments. The thoracic, lumbar, or conus
medullaris locations are less common.
Spinal Cord Astrocytomas represent a mixed group with respect to
histology, gross characteristics, biology, and natural history. They
range from benign to malignant. These tumors include low-grade
fibrillary and pilocytic astrocytomas, malignant astrocytomas,
glioblastomas, gangliogliomas, and the rare oligodendroglioma.
Approximately 25% of adult astrocytomas are malignant.
The borderline between low-grade and Anaplastic (Malignant) Astrocytoma,
is at best indistinct. Although many patients with low-grade
Astrocytomas survive for extended periods, 50% of surgically treated
lesions evolve into Anaplastic Astrocytomas or Glioblastomas.
Degeneration into a higher-grade neoplasm is the most common cause
of death in patients with low-grade Astrocytomas.
Low-grade Astrocytomas are uncommon tumors and occur less frequently
than their more malignant counterparts. They are generally found in
a younger population and have a more favorable prognosis. Their true
incidence is difficult to determine, because sampling and grading
vary substantially. Low-grade Astrocytoma probably represents 10% to
15% of gliomas. These are neoplasms of children and adults from 20 to
40 years of age. These tumors are rare in older adults. Low-grade
Astrocytomas can present with any of the symptoms previously
described.
Anaplastic Astrocytomas are among the most common primary malignant
spinal cord tumors. These tumors represent approximately one third
of all Astrocytomas and about one quarter of all gliomas. They occur
at any age but typically are found in older patients. Their peak
incidence is in the fifth and sixth decades of life.
Malignant Astrocytomas generally have a poor prognosis, with an
average survival of two (2) years. Both types of malignant Glial
tumors (Anaplastic Astrocytomas and Glioblastomas) spread through
the extracellular space and along the compact white matter tracts
that travel through the spinal cord.
GBMs are the most common and most malignant of the primary CNS
neoplasms, representing 15% to 20% of these tumors. Approximately
half of all Astrocytomas are GBMs.
GBMs usually occur in patients over 50 and are unusual in patients
under 30. Like Anaplastic Astrocytomas, GBMs can occasionally be
found at any age.
Along with primary CNS Lymphoma, GBMs have the worst prognosis of
all primary tumors. GBMs disseminate early, rapidly, and widely.
Central Nervous System spread is common, but distant metastasis
is rare.
Oligodendrogliomas are uncommon gliomas. These tumors arise from glial
cells, called Oligodendrocytes (the cells that are responsible for
creating and maintaining myelin, which is the insulating substance
around the axons of spinal cord fibre networks). They are much less
common than Astrocytes. These are tumors of adults, with the peak
incidence being between 35 and 45 years of age.
It is important to recognize that a significant percentage of
Astrocytoma tumors may also have an Oligodendroglioma component as
well. These tumors are called "Mixed Gliomas". Treatment
of a Mixed Glioma is similar to what is described for an
Astrocytoma.
Most Oligodendrogliomas are slow-growing tumors. Tumor grade is the
single most important prognostic variable.
Once again, MRI (without and with Gadolinium as a "contrast" agent)
is the primary method to diagnose these tumors, since it affords
diagnostic anatomical details including the position of the tumor
and its relationship to the spinal cord.
Surgery is the most effective treatment for most intramedullary
spinal cord tumors. The goal of surgery is determined primarily by
the nature of the interface between the tumor and the spinal cord.
Our strong preference favors Minimally Invasive Microsurgical Gross
Total Removal of a benign tumor or in any tumor where there is a
clear demarcation/interface between the tumor and the spinal cord.
Surgical removal alone provides long-term tumor control or cure for
hemangioblastomas, almost all ependymomas, and some well-circumscribed
astrocytomas.
Determination of the resectability of an intramedullary tumor is best
made by direct intraoperative inspection of the tumor-spinal cord
interface.
It is imperative to understand that Astrocytomas are "infiltrative",
and as such, their nature is to spread along the interconnecting
fiber pathways (tracts) of the spinal cord. Therefore, it is
unlikely that surgery will ever be the definitive treatment for
many of these neoplasms.
Aggressive surgical excision of the tumor is advocated in most
patients. The goal is to reduce the maximum amount of the tumor.
When tumor is within the substance of the spinal cord, an aggressive
internal decompression of the tumor is warranted. There are some
advanced technologies that currently assist in the extent of
resection. The ability of the surgeon to "visualize" tumor is
somewhat limited. Magnification of vision, Intraoperative
ultrasound imaging, and Intraoperative Fluorescence techniques
are a few of the adjunctive technologies that may be available
to assist maximum resection, while limiting the risk of injuring
adjacent functioning spinal cord.
The surgeon may choose to reserve a small part of the tumor for
tissue culture and sensitivity testing against various
chemotherapeutic agents. It can be helpful to know beforehand, if
a certain drug has any or limited effectiveness against this
particular tumor, in this particular patient.
In selecting the treatment of High Grade Malignant Astrocytomas, it
should be kept in mind that the following three (3) statistically
independent factors affect the length of survival: 1) age at the
time of diagnosis, 2) histological features (Grade of the tumor
and additional characteristics such as Mitotic Index), and 3)
performance status (the level of the patient's neurological
capabilities). Older patients with high grade malignant spinal
cord tumors, who are in poor neurological condition at the time
of surgery, do less well.
Tumors that cannot be totally resected, or are recognized to be
more aggressive, will require post-operative radiation therapy and
possibly chemotherapy as well. Long-term outcome and risk of
recurrence depend primarily on tumor histology, the completeness
of the original resection and responsiveness to radiation and /or
chemotherapy.
Radiation therapy continues to have an important place in the
treatment of many of these tumors and will be the second major
treatment option, in a comprehensive therapeutic program, for most
patients.
Radiation therapy is the primary form of non-surgical treatment. It
is rarely administered to the whole spinal cord; newer forms of
Radiosurgery (Focused Beam Radiation) allow for very precise
focusing of radiation beams into the area of tumor involvement,
with less risk for damage to the surrounding spinal cord.
Radiosurgery (Focused Beam Radiation) has made this spinal cord
radiation treatment less toxic than in previous years. This
exceptionally accurate radiation therapy system may someday be
useful in the management of intradural extramedullary as well as
intramedullary spinal cord tumors.
Consideration to WITHOLD radiation therapy may be appropriate in
cases of gross total surgical removal, or incomplete removal, or
in some cases of low grade Astrocytoma. Meticulous follow up is
required, since radiation therapy can be helpful where tumor
recurrence or progression is documented.
Chemotherapy is the third arm of this comprehensive effort to prolong
and maintain a high quality of life.
Traditional management has been to use "standard" forms of
chemotherapy. Currently there are some unconventional chemotherapeutic
alternatives that offer considerable hope for improved quality and
length of survival. New therapies such as Temodar
(temozolamide), Avastin (bevacizumab which is an
anti-angiogenesis medication) and CPT-11 are currently being
used by one of our Neuro-oncologists either alone (or more commonly)
in combination or with other drugs, to produce encouraging results.
Additional information regarding these treatments is available at
the "Virtual Trials" website.
Patients suffering from spinal cord tumors often require extensive
and prolonged medical care, which involves a large multidisciplinary
team comprising medical, surgical, neuroradiological, radiotherapy,
neuro-oncological and rehabilitation specialists.
This team of specialists, involved in comprehensive programs, are
an important factor in the successful management of patients with
spinal cord tumors.
Ultimately we hope to see the availability of specific gene
therapies to treat tumors of the spinal cord such as Astrocytomas
and other Primary Central Nervous System Tumors.
Several patients with Spinal Cord Tumors are presented to
illustrate the differences in these clinical problems. An example
of a complete resection of a Filum Terminale Ependymoma is
contrasted with another case in order to demonstrate the issue of
dense adherence to nerve roots, which limits the reasonable
possibility of complete respectability.
Patients with Spinal Cord Meningioma and Neurofibroma are included
as well.
Case 1. Jeremy Lugan is a 19 year old male with a three (3) month
history of lower back and right hip, groin and flank pain. Jeremy's
neurological examination was negative for any deficits. MRI
demonstrated an ovoid "enhancing" intradural mass lesion.
(INSERT MRI scans AP & LATERAL views)
A complete resection of a Filum Terminale Ependymoma was accomplished.
Jeremy is free of any neurological deficits.
(INSERT SURGICAL PHOTOS/VIDEO)
Case 2. Gregory Dunkle is a 38 year old male with a 4 year history of
lower back pain. He had diminished pin prick sensation in his feet
on both sides. MRI scan showed an ovoid intradural "enhancing" mass
at the L2 and L3 levels. There was a smaller "enhancing" lesion 2
vertebral segments below the larger one.
(INSERT MRI scans AP & LATERAL views)
The surgery consisted of a Minimally Invasive Microsurgical Bilateral
L2 and L3 Laminectomy using a Unilateral (one sided) Approach.
The tumor proved to be a Myxopapillary Ependymoma. The tumor
"invaded" the pia arachnoid (the membrane directly adherent to the
nerve root) of many nerve roots making a complete and total
resection impossible, without sacrificing the major nerve roots.
The vast majority (over 98 per cent) of the large tumor was removed.
Subsequent radiation therapy (to include the smaller more distal
"seeded" tumor as well) and chemotherapy has been well tolerated.
(INSERT SURGICAL PHOTOS/VIDEO)
A Minimally Invasive Microsurgical Costo-transversectomy
(removal of the head of a rib and the transverse process of the
vertebra to which the rib attaches) and Bilateral Laminectomy
at T7 and T8 was carried out using a Unilateral (one sided)
Approach. A complete resection of the calcified Meningioma
was accomplished. Mrs. Myrick-Haynes noticed improvement in leg
function shortly after surgery. She began to walk several days
post-operatively and continues to enjoy steady improvement to
unassisted walking.
(INSERT SURGICAL PHOTOS/VIDEO)
Mr. Irvin Harbour is a 61 year old male CT scan technician with a
6 month history of lower back and bilateral leg pain. An MRI scan
demonstrated an ovoid "enhancing" mass at the L1 (Lumbar) level.
(INSERT MRI scans AP & LATERAL views)
The surgical approach consisted of a Minimally Invasive
Microsurgical Bilateral L1 and L2 Laminectomy using a Unilateral
Approach. Complete resection of a large Neurofibroma embedded
within the Cauda Equina (nerve roots) was carried out. Mr. Harbour
was mobilized within a short period of time post-operatively and
went home on the second post-operative day.
(INSERT SURGICAL PHOTOS/VIDEO)
Messrs. Lugan, Dunkle and Harbour and Ms. Myrick-Haynes' results are
usual of these types of operation. Each patient's recovery differs
and depends on many factors. Age, sex, type and amount of disability
and length of symptoms all play a role in the recovery process. Our
treatment goal in all cases is to allow the patient to resume all
the activities they did prior to their injury whenever possible.
There are two (2) general "guidelines" regarding recovery of
neurological function:
- Recovery is less likely to be complete in the older patient,
patients in whom the symptoms & signs have been present for extended
periods of time and the neurological deficits are more severe.
- Whatever neurological deficits remain at a point one (1) year
after surgical treatment are most likely to be permanent.
* Mrs. Myrick-Haynes and Messrs. Dunkle, Harbour and
Lujan have signed a release to permit the sharing of this personal
information. We will not disclose any information unless the parties
involved agree in writing. Mrs. Myrick-Haynes and Mr. Harbour chose
to permit this information because of their gratitude to Dr. Martin
L. Lazar and his staff.
Every effort has been made by the author(s) to provide accurate,
up-to-date information. However, the medical knowledge base is dynamic
and errors can occur. By using the information contained herein, the
viewer willingly assumes all risks in connection with such use.
Neither the author nor Neurosurgical Consultants, p.a. shall be
held responsible for errors, omissions in information herein nor
liable for any special, consequential, or exemplary damages resulting,
in whole or in part, from any viewer(s)' use of or reliance upon,
this material.
Clinical information is provided for educational purposes and not as
a medical or professional service. Person(s) who are not medical
professionals should have clinical information reviewed and
interpreted or applied only by the appropriate health
professional(s).
For additional information or to have your Spinal Cord Tumor reviewed,
please contact our office.
Return to Top of Page
This page last edited on 2/20
|
|